Oral Ketamine Safety and Efficacy: The Evidence

The question patients and clinicians most need answered about ketamine tablets is straightforward: does it work, and is it safe? This guide examines the clinical evidence systematically — what the trials show about efficacy, what the safety data reveal about risks, and how to interpret the strengths and limitations of the current evidence base.

Unlike many treatments that have been studied for decades across thousands of patients, ketamine tablet research is still maturing. Understanding what we know, what we do not know, and what the data genuinely support helps patients make informed decisions and clinicians practice evidence-based medicine. For a summary of the key studies, see our article on key clinical trials.

Efficacy Evidence

The Depression Evidence Base

Treatment-resistant depression (TRD) is the most extensively studied indication for ketamine tablets. The evidence comes from several study types, each with different strengths.

Randomized Controlled Trials

RCTs are the gold standard of clinical evidence. For ketamine tablets specifically:

Jafarinia et al. (2016): A 46-patient RCT comparing ketamine tablets to diclofenac (an active comparator) as adjuncts to existing antidepressant therapy. Ketamine showed statistically significant greater MADRS score reductions at 6 and 12 weeks. This was one of the first controlled comparisons for oral ketamine in depression.

Swainson et al. (2020): A 27-patient double-blind pilot RCT comparing ketamine tablets (0.5-3.0 mg/kg, flexible dosing) to oral midazolam (active placebo) over 4 weeks. Ketamine showed significantly greater antidepressant response. The use of midazolam as an active placebo was methodologically important — it controlled for the non-specific sedative effects of ketamine.

Iglewicz et al. (2015): A 40-patient placebo-controlled RCT in palliative care patients with depression. Ketamine tablets (0.5 mg/kg daily) produced significant depression score reductions within 3 days — faster than any conventional antidepressant. This remains one of the few true placebo-controlled studies of oral ketamine.

Open-Label Studies

While less rigorous than RCTs, open-label studies provide important data on response rates and tolerability:

Lara et al. (2013): 26 patients with TRD received oral ketamine 0.5 mg/kg daily for 21 days. Response rate was 77%, with 31% achieving remission. Effects appeared within the first week.

Domany et al. (2019): 31 patients with TRD received sublingual ketamine 1 mg/kg. Response rate was 74% at Day 7, with effects beginning within 1-2 days.

Glue et al. (2020): Extended follow-up study documenting sustained response over 6 months in patients who initially responded to oral ketamine.

What the Depression Data Collectively Show

Drawing across all available studies:

• Response rates: 50-77% in open-label studies; somewhat lower in controlled trials (consistent with the general pattern that controlled trials show lower effect sizes than open-label studies)
• Onset: 24-72 hours in most studies — dramatically faster than the 4-6 week onset of SSRIs and SNRIs
• Duration of effect: Individual dose effects last days to weeks; sustained effects require ongoing dosing
• Effect size: Moderate to large, comparing favorably to conventional antidepressants in TRD populations
• Consistency: Every published study has found a positive signal for ketamine tablets in depression, though effect sizes and quality vary

The Pain Evidence Base

Oral ketamine for pain has a longer clinical history but a similarly limited formal evidence base:

Chronic neuropathic pain: Multiple studies demonstrate analgesic effects of oral ketamine in neuropathic pain conditions. Effective doses are generally lower than those used for depression, and the mechanism involves NMDA receptor antagonism reducing central sensitization.

Cancer/palliative pain: Oral ketamine has been used in palliative care since the 1990s. Evidence includes several small RCTs and numerous case series documenting benefit in opioid-refractory cancer pain.

CRPS: Case series and small trials support oral ketamine as part of multimodal CRPS treatment, though large RCTs are lacking.

Fibromyalgia: Limited but positive evidence from small studies and clinical experience.

The pain evidence shares the same general limitation as the depression evidence: small samples, limited controls, and heterogeneous protocols. However, the longer clinical history provides substantial observational data supporting safety and efficacy in pain management.

Anxiety and PTSD Evidence

The evidence base for ketamine tablets in anxiety and PTSD is the least developed:

• Most evidence is extrapolated from IV ketamine studies or from depression studies where anxiety was a secondary outcome
• Patients with comorbid depression and anxiety frequently report improvement in both conditions
• Dedicated RCTs of oral ketamine for primary anxiety disorders are needed
• PTSD-specific data is primarily from case reports and small series

Comparative Efficacy: Oral vs. IV

A critical clinical question is whether oral ketamine is as effective as IV. The honest answer is nuanced:

Per session: IV ketamine generally produces a larger, more reliable acute antidepressant effect. The 100% bioavailability and rapid onset create a more intense neuroplasticity-promoting experience.

Over time: With repeated dosing, oral ketamine can achieve comparable sustained outcomes. The NMDA receptor modulation and downstream plasticity mechanisms are activated by both routes.

Maintenance: For long-term maintenance therapy, oral ketamine may have practical advantages — the ability to dose at home, lower cost, and less disruption to daily life may improve adherence and sustained treatment.

Evidence quality: IV ketamine has a substantially larger evidence base, including multiple large RCTs. Direct head-to-head comparisons of IV vs. oral are limited.

Safety Evidence

Side Effect Profile

The safety data from clinical trials and clinical practice paint a consistent picture of ketamine tablet side effects:

Common Side Effects (reported by more than 10% of patients)

Dissociation (30-60%):

• Ranges from mild detachment ("things seem slightly unreal") to moderate perceptual changes
• Onset 30-60 minutes after dosing; resolves within 2-4 hours
• Intensity typically decreases with repeated dosing as tolerance develops
• Some clinicians and patients consider mild dissociation a marker of therapeutic dosing

Nausea (20-40%):

• Most common in the first 1-2 hours after dosing
• Often improves with repeated dosing
• Manageable with ondansetron (Zofran) or ginger supplements
• Taking the dose on a completely empty stomach can worsen nausea in some patients; a very light snack 30 minutes before may help

Sedation (30-50%):

• Drowsiness during and after dosing
• Duration 2-6 hours depending on dose
• Evening dosing accommodates this effect
• Does not typically persist to the following day at therapeutic doses

Dizziness (20-30%):

• Lightheadedness during onset and peak effects
• Resolves as the dose wears off
• Patients should remain seated or lying down during peak effects

Elevated blood pressure (10-20%):

• Transient increases of 10-20 mmHg systolic, 5-10 mmHg diastolic
• Peaks with drug peak effect, resolves as the drug clears
• Clinically significant in patients with pre-existing hypertension
• Home blood pressure monitoring during dosing sessions is recommended

Cognitive effects (15-25%):

• Temporary difficulty with word-finding, concentration, short-term memory
• Resolves completely within hours of dosing
• Not associated with persistent cognitive impairment at therapeutic doses
• More pronounced at higher doses

Uncommon Side Effects (reported by 1-10% of patients)

• Headache (5-10%)
• Vivid dreams or nightmares (3-8%)
• Anxiety or agitation during onset (3-7%)
• Blurred vision (2-5%)
• Dry mouth (3-5%)
• Tachycardia (2-5%)
• Urinary urgency (1-3%)

Rare Side Effects (reported by fewer than 1% of patients)

• Severe dissociative reactions requiring clinical intervention
• Psychotic-like symptoms (paranoia, hallucinations beyond typical dissociation)
• Significant cardiac arrhythmia
• Severe hypertensive episode
• Allergic reaction

Serious Safety Concerns

Urological Toxicity

The most well-known serious risk of chronic ketamine use is bladder damage — ketamine-induced cystitis. Key points:

What happens: Chronic ketamine exposure can cause inflammation and scarring of the bladder lining, leading to reduced bladder capacity, painful urination, frequency, urgency, and in severe cases, bladder contracture requiring surgical intervention.

Dose dependence: This is overwhelmingly documented at recreational doses (typically grams per day over months to years). The therapeutic dose range for ketamine tablets (typically <300 mg per session, 2-3 times weekly) is substantially lower.

Risk at therapeutic doses: While not zero, the risk at standard therapeutic doses appears to be very low. Case reports of urological symptoms in therapeutic patients are rare but do exist, primarily in long-term users at the upper end of the dose range.

Monitoring: All patients on chronic ketamine tablet therapy should be monitored for urinary symptoms. Any new urgency, frequency, dysuria, or hematuria should prompt urological evaluation and consideration of dose reduction or discontinuation.

Reversibility: Early-stage ketamine cystitis is generally reversible with cessation. Advanced cases may cause permanent damage.

Hepatotoxicity

Liver injury has been reported in association with chronic ketamine use:

• Primarily documented at high doses or with concurrent hepatotoxic drug use
• Manifests as elevated liver enzymes (AST, ALT)
• Rare cases of clinically significant hepatitis
• Baseline liver function tests before starting therapy are recommended
• Periodic monitoring (every 3-6 months) during chronic use
• Dose reduction or discontinuation if significant elevation occurs

Cardiovascular Risks

Ketamine's sympathomimetic effects raise blood pressure and heart rate:

• Transient and generally modest at oral therapeutic doses
• More concerning in patients with baseline hypertension, coronary artery disease, or cerebrovascular disease
• Uncontrolled hypertension is a contraindication
• Blood pressure monitoring during dosing sessions is standard practice
• Rarely, significant hypertensive episodes occur; patients should have a plan for managing elevated blood pressure

Abuse and Dependence Potential

As a Schedule III controlled substance, ketamine has recognized abuse potential:

Physical dependence: Uncommon at therapeutic doses and frequencies. Abrupt discontinuation does not typically produce a withdrawal syndrome, though symptom recurrence is common.

Psychological dependence: Can develop, particularly in patients with a history of substance use disorders or those who find the dissociative experience rewarding. Warning signs include dose escalation without prescriber approval, taking doses more frequently than prescribed, and preoccupation with the dosing experience.

Tolerance: Tolerance to dissociative effects develops reliably with repeated use, which is generally considered benign (patients need less dose adjustment over time as subjective effects stabilize). Tolerance to therapeutic effects is less clearly documented and remains an area of clinical debate.

Mitigation: Proper patient selection (screening out active substance abuse), controlled dispensing, regular clinical follow-up, and honest prescriber-patient communication about appropriate use.

Psychotomimetic Effects

In rare cases, ketamine can produce symptoms resembling psychosis:

• Paranoid ideation, auditory or visual hallucinations, thought disorganization
• More common at higher doses and in individuals with psychotic vulnerability
• Patients with a personal or strong family history of schizophrenia or schizoaffective disorder are generally excluded
• Distinguished from typical dissociation by the presence of distress, paranoia, or loss of reality testing
• Generally resolves as the drug clears; persistent symptoms are exceedingly rare at therapeutic doses

Long-Term Safety Data

The honest assessment of long-term safety is that comprehensive data is limited:

What we know:

• Clinical use of oral ketamine for pain extends to the 1990s; no epidemic of serious adverse effects has been documented
• Published case series of patients treated for 6-24 months generally report acceptable tolerability
• The pediatric anesthesia literature provides decades of safety data for acute ketamine use (though at different doses and routes)

What we do not know:

• The effects of 5, 10, or 20 years of therapeutic oral ketamine use on brain structure or function
• Whether very low-level urological or hepatic changes accumulate over decades
• The long-term effects on cognitive function with chronic use
• Whether repeated glutamatergic stimulation over years has consequences not yet identified

How to interpret this uncertainty: The absence of identified long-term harm is reassuring but not conclusive. Patients starting ketamine tablet therapy should be aware that they are, to some extent, accepting uncertainty about very long-term effects — similar to many psychiatric medications that were prescribed for years before comprehensive long-term data was available.

Monitoring Protocols

Baseline Assessment

Before starting ketamine tablet therapy, the following should be established:

Medical evaluation:

• Complete medical history with attention to cardiovascular, hepatic, and urological health
• Blood pressure and heart rate measurement
• Liver function panel (AST, ALT, alkaline phosphatase, bilirubin)
• Basic metabolic panel
• Urinalysis
• Consider baseline cognitive screening for patients at higher risk

Psychiatric evaluation:

• Comprehensive diagnostic assessment
• Suicide risk evaluation
• Substance use history (current and past)
• Assessment of psychotic symptoms or vulnerability
• Documentation of prior treatment trials and responses
• Evaluation of treatment goals and expectations

Informed consent:

• Off-label status of treatment
• Known risks and common side effects
• Unknown long-term risks
• Alternative treatment options
• Cost and insurance considerations
• Expectations for monitoring and follow-up

Ongoing Monitoring Schedule

Red Flags Requiring Immediate Attention

The following should prompt urgent reassessment:

• Systolic blood pressure above 180 mmHg or diastolic above 110 mmHg during a dosing session
• Severe dissociative reaction with persistent distress, paranoia, or reality testing loss
• New urinary symptoms (frequency, urgency, pain, blood in urine)
• Significant liver enzyme elevation (more than 3x upper limit of normal)
• Suicidal ideation increasing despite or during treatment
• Signs of medication misuse (requesting early refills, dose escalation without prescriber knowledge)
• Severe persistent nausea or vomiting preventing adequate hydration

Patient Selection

Who Is a Good Candidate

Ketamine tablets are most appropriate for patients who:

• Have documented treatment-resistant depression (failed 2+ adequate antidepressant trials)
• Have chronic pain conditions poorly responsive to conventional treatment
• Are medically stable with no significant cardiovascular, hepatic, or urological disease
• Have no active psychotic disorder or schizophrenia spectrum diagnosis
• Have no active substance abuse
• Can comply with monitoring requirements
• Have a treatment monitor available during home dosing
• Understand and accept the off-label nature and known risks
• Have realistic expectations about treatment outcomes

Who Is Not a Good Candidate

Ketamine tablets should generally be avoided in:

• Active psychosis or schizophrenia spectrum disorders
• Uncontrolled hypertension (systolic above 160 or diastolic above 100 despite treatment)
• Active substance abuse, particularly stimulants, PCP, or dissociatives
• Severe hepatic impairment
• Active interstitial cystitis or significant bladder pathology
• Pregnancy or planned pregnancy
• Patients unable to comply with monitoring or dosing protocols
• Patients seeking ketamine primarily for the dissociative experience rather than therapeutic benefit

Risk Stratification

Patients can be stratified by risk level to guide monitoring intensity:

Lower risk: Young to middle-aged, medically healthy, no cardiovascular disease, no substance use history, first episode of TRD, strong social support. Standard monitoring protocol.

Moderate risk: Older age, controlled hypertension, remote substance use history, comorbid medical conditions, multiple prior treatment failures. Enhanced monitoring with more frequent blood pressure checks, liver function tests, and clinical visits.

Higher risk: Borderline cardiovascular parameters, concurrent hepatotoxic medications, recent substance use in remission, complex comorbidities. Consider whether the risk-benefit ratio favors ketamine vs. alternatives; if proceeding, intensive monitoring is essential.

Interpreting the Evidence: Strengths and Limitations

Strengths of the Current Evidence

• Consistency: Every published study of ketamine tablets for depression shows a positive signal
• Biological plausibility: The glutamatergic mechanism is well-characterized and distinct from existing antidepressants
• Speed of onset: The rapid antidepressant effect is reproduced across multiple studies, designs, and populations
• Clinical history: Decades of clinical use in pain and anesthesia provide substantial real-world safety data
• Mechanistic support: Preclinical evidence strongly supports the NMDA-mTOR-BDNF synaptogenesis pathway

Limitations of the Current Evidence

• Small sample sizes: No individual RCT of oral ketamine has enrolled more than 50 patients
• Limited long-term data: Most studies follow patients for weeks to months, not years
• Publication bias: Positive studies are more likely to be published; negative trials may go unreported
• Heterogeneous protocols: Doses, frequencies, formulations, and outcome measures vary between studies, making meta-analysis difficult
• Limited diversity: Most studies have been conducted in predominantly white, Western populations; generalizability to other demographics is uncertain
• Placebo challenges: Ketamine's subjective effects make true blinding difficult; active placebos (midazolam) help but do not fully solve this problem
• No Phase 3 data for oral formulation: Unlike Spravato (esketamine nasal spray), no oral ketamine product has completed Phase 3 registration trials

What This Means for Patients

The evidence supports a reasonable but not definitive conclusion: ketamine tablets are likely effective for treatment-resistant depression and certain pain conditions, with an acceptable safety profile in appropriately selected and monitored patients.

This is not the same as established first-line treatments like SSRIs, which have decades of large-scale RCT data. Patients choosing ketamine tablet therapy should understand they are accepting a treatment with strong theoretical and preliminary clinical support but limited definitive evidence — and should weigh this against the severity of their condition and the failure of conventional alternatives.

The Future of Ketamine Tablet Evidence

Several developments will strengthen the evidence base in coming years:

• Phase 2/3 clinical trials: Pharmaceutical companies (notably Clexio Biosciences) are advancing extended-release ketamine tablet formulations through registration trials
• Large academic RCTs: Multiple academic centers globally are conducting larger, more rigorous oral ketamine trials
• Real-world evidence: Registries and electronic health record data from the growing number of patients receiving oral ketamine will provide important safety and effectiveness data
• Long-term follow-up: Extended studies tracking patients for years rather than weeks will address the most critical gap in current knowledge
• Biomarker development: Identification of blood-based or neuroimaging biomarkers that predict response could improve patient selection and dosing

As this evidence accumulates, the clinical picture for ketamine tablets will come into sharper focus — either confirming the promising early results or revealing limitations not yet apparent.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• Mayo Clinic: Treatment-Resistant Depression — Mayo Clinic resource on treatment-resistant depression diagnosis, management, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches